Atlas Venture Life Science Advisors LLC Sells 1,178,137 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Atlas Venture Life Science Advisors LLC lowered its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 15.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,430,257 shares of the company's stock after selling 1,178,137 shares during the quarter. Day One Biopharmaceuticals comprises approximately 9.8% of Atlas Venture Life Science Advisors LLC's investment portfolio, making the stock its 4th biggest holding. Atlas Venture Life Science Advisors LLC owned 7.36% of Day One Biopharmaceuticals worth $106,228,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Quest Partners LLC acquired a new stake in shares of Day One Biopharmaceuticals in the fourth quarter valued at approximately $29,000. Quintet Private Bank Europe S.A. boosted its holdings in shares of Day One Biopharmaceuticals by 43.2% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company's stock valued at $48,000 after acquiring an additional 1,000 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Day One Biopharmaceuticals by 352.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,067 shares of the company's stock valued at $147,000 after acquiring an additional 7,841 shares in the last quarter. Exchange Traded Concepts LLC boosted its holdings in shares of Day One Biopharmaceuticals by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company's stock valued at $147,000 after acquiring an additional 2,554 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of Day One Biopharmaceuticals in the fourth quarter valued at approximately $156,000. Institutional investors and hedge funds own 87.95% of the company's stock.

Insider Activity at Day One Biopharmaceuticals

In related news, General Counsel Adam Dubow sold 3,253 shares of the company's stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $16.08, for a total value of $52,308.24. Following the completion of the sale, the general counsel now owns 21,731 shares in the company, valued at approximately $349,434.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 10,000 shares of the stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $16.02, for a total value of $160,200.00. Following the completion of the sale, the insider now owns 1,174,662 shares in the company, valued at approximately $18,818,085.24. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, General Counsel Adam Dubow sold 3,253 shares of the stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $16.08, for a total transaction of $52,308.24. Following the completion of the sale, the general counsel now owns 21,731 shares of the company's stock, valued at approximately $349,434.48. The disclosure for this sale can be found here. In the last 90 days, insiders sold 185,534 shares of company stock worth $3,207,830. 8.40% of the stock is owned by corporate insiders.

Day One Biopharmaceuticals Stock Up 2.7 %

NASDAQ:DAWN traded up $0.39 during trading hours on Thursday, reaching $15.10. 1,064,643 shares of the company's stock were exchanged, compared to its average volume of 889,323. The company has a market capitalization of $1.32 billion, a P/E ratio of -6.02 and a beta of -1.51. Day One Biopharmaceuticals, Inc. has a 12 month low of $9.67 and a 12 month high of $18.07. The business's 50-day simple moving average is $14.22 and its two-hundred day simple moving average is $14.75.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last issued its earnings results on Monday, May 6th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.05). As a group, sell-side analysts anticipate that Day One Biopharmaceuticals, Inc. will post -2.69 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on DAWN shares. Wedbush reiterated an "outperform" rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Tuesday, May 7th. Needham & Company LLC reiterated a "buy" rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Wednesday, June 19th. Piper Sandler reiterated an "overweight" rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a report on Monday. JPMorgan Chase & Co. increased their price objective on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an "overweight" rating in a report on Monday, April 22nd. Finally, HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, June 20th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Day One Biopharmaceuticals has an average rating of "Moderate Buy" and an average price target of $37.67.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.